Alan Heller, Chairman
Alan Heller has over 35 years of leadership experience in the healthcare industry. Mr. Heller currently holds a position as an Operating Partner at Water Street and serves as Chairman of the Board of Celerity Pharmaceuticals and a Board Member of BioClinica. He holds an MBA from DePaul University and a BS from the University of Illinois, Chicago.
Vipin Garg, Ph.D.
Vipin Garg, Ph.D., served as the Chief Executive Officer and a member of the Neos Therapeutics, Inc., board of directors since October 2013, and was named our President in July 2014. Prior to joining us, Dr. Garg served as President, Chief Executive Officer and a director of Tranzyme Inc., now Ocera Therapeutics, Inc. (NASDAQ: OCRX) from September 2001 to July 2013. Dr. Garg has also served as Vice President of Operations and Business Development, and later Chief Operating Officer, of Apex Bioscience, Inc. from 1994 to 2000, as Vice President of Development at DNX Bio-Therapeutics, Inc. from 1992 to 1994, as Director of Technical Services and Marketing at Sepracor, Inc., now Dainippon Sumitomo Pharma, from 1989 to 1992, and as Manager, Contract Services at Bio-Response Inc. from 1986 to 1989. Dr. Garg has served on the board of North Carolina Biotechnology Center and on the Executive Committee of CED (formerly the Council for Entrepreneurial Development), and is the recipient of the Ernst & Young Entrepreneur of the Year Award for the Carolinas Region in 2009. Dr. Garg received his Ph.D. in Biochemistry from the University of Adelaide, Australia, his M.Sc. from the Indian Agricultural Research Institute in New Delhi, India, and his B.Sc. from Meerut University, India.
Bryant Fong is a founding General Partner at Biomark Capital, a life sciences private equity fund formed in 2013. Prior to Biomark Capital, Mr. Fong was a Managing Director at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnology industry. Some of Mr. Fong’s notable investments include Pharmasset, Galapagos, Ferrokin Biosciences, Ceptaris Therapeutics, and Novadaq Technologies. Mr. Fong currently serves on the Boards of Directors of a number of private life science companies. Mr. Fong graduated with honors in Biochemistry from the University of California at Berkeley.
Greg Robitaille is responsible for corporate development at Water Street, where he manages the strategic development and acquisition activities of the firm’s specialty health care distribution companies. Mr. Robitaille also spent 10 years with Equity Group Investments, the primary investment company of Sam Zell. He holds a Bachelor’s degree from Hamilton College and an MBA from Columbia University.
John Schmid has served on our board of directors since June 2015. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc., a publicly traded biotechnology company, from September 2013 until its sale to Teva Pharmaceuticals, Inc. (NYSE: TEVA) in June 2015. Prior to that, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) in September 2013. Mr. Schmid also served as Chief Financial Officer at GeneFormatics, Inc. from 1998 to 2003 and as Chief Financial Officer at Endonetics, Inc. from 1995 to 1998. He currently serves as chairman of the board of directors of Speak, Inc. Mr. Schmid holds a B.A. in Economics from Wesleyan University and an M.B.A. from the University of San Diego.
Paul R. Edick
Paul R. Edick has served on our board of directors since June 2015. He is currently the Managing Partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities, a company he founded in 2007. From July 2010 until November 2014, Mr. Edick was the Chief Executive Officer of Durata Therapeutics, which was merged with Actavis plc (NYSE: ACT) in November 2014. Prior to that, Mr. Edick was Chief Executive Officer of Ganic Pharmaceuticals from 2008 to 2010, Chief Executive Officer of MedPointe Healthcare Inc. from 2006 to 2008, and President of Pharmaceutical Operations at MedPointe from 2002 to 2006. Mr. Edick has served on the boards of directors of NewLink Genetics Inc. (NASDAQ: NLNK) and Circassia Ltd. (LSE: CIR.L) since 2011. Mr. Edick holds a B.A. in Psychology from Hamilton College in Clinton, NY.
Beth Hecht joined Neos Therapeutics Board of Directors in September 2015. Beth serves as Managing Director and Chief Legal and Administrative Officer of Auven Therapeutics, a global private equity firm with offices in the U.S., Bermuda, St. Thomas USVI and Switzerland that acquires and develops pharmaceutical products that address unmet medical needs. She has over twenty years of senior management experience in the pharmaceutical and biotechnology industries, building and leading legal, compliance and security teams at companies including Durata Therapeutics Inc., MedPointe Inc., Warner Chilcott PLC, ChiRex, Ltd. and Alpharma Inc. Ms. Hecht started her career as an attorney specializing in corporate transactions and intellectual property at Willkie Farr & Gallagher and then Kirkland & Ellis. Ms. Hecht received a J.D. from Harvard Law School and a B.A. from Amherst College.